CLOs on the Move

Cumberland Pharmaceuticals

www.cumberlandpharma.com

 
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. With a focus on underserved niche markets, including hospital acute care and gastroenterology, we deliver products that serve patients in the U.S. market. Cumberland also makes its products available to patients internationally through select strategic partnerships. We own the worldwide rights to all our brands. While Cumberland`s commercial capabilities are focused on the U.S. market, our business development team is actively pursuing opportunities to make our brands available to patients in markets around the ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

International Partnership for Microbicides

Developing HIV prevention products for women worldwide

AN2 Therapeutics

AN2 Therapeutics is a biopharmaceutical company that develops therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.

Syntiron

Syntiron is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardiology Associates

Cardiology Associates of Alabama offers vascular care and heart treatments including structural heart, interventional procedures, pediatric cardiology, heart rhythm disorders, and congestive heart failure.

KCR

KCR is a clinical development solutions provider for the biotechnology, pharmaceutical, and medical device industries. We support clients with full-service clinical development capabilities across three main areas: Trial Execution, Consulting and Placement. KCR operates across four main regions: North America, Western Europe, Central Europe, and Eastern Europe, with a main operational hub located in Boston, MA. Our strategic hub locations, technical capabilities and solution offerings allow for the optimized delivery of trial execution strategies to develop life-changing therapies. KCR offers access to an estimated population of 1.1 Billion people.